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ABSTRACT 
 
Background and aims: Endoscopic Submucosal Dissection (ESD), an endoscopic technique used 
for treatment of gastric superficial lesions, has been gaining importance on western countries. 
Procedural times have an impact on various outcomes. Our aim is to define which factors from patients, 
lesions and procedure can predict longer procedural times. 
Methods: In a cohort of 127 lesions resected by ESD with IT-knife by experienced 
gastroenterologists, characteristics from the patient (age, gender, presence of co-morbidities, usage and 
suspension of anti-platelet drugs and general physical condition), lesion (size, histopathological 
diagnosis at biopsy, location, macroscopic type and submucosal invasion) and procedure (complications) 
were retrospectively analyzed for its impact on time of procedure. Univariate and multivariate analysis 
were performed. 
Results: Lesions larger than 20mm (p<0.001), on the upper third of the stomach (p=0.035) and 
with an ASA score of 3 (p=0.031) were considered influential factors for a longer procedure time and 
specifically for a time of procedure longer than 90 minutes. Existence of intra-procedure complications 
was also a predictor for a procedure time >90 minutes. Lesion’s size >20mm and location in the upper 
third were independently associated with a procedure time longer than 90 minutes (OR 4.91[95%CI 
2.29-10.50] and OR 18.26 [95%CI 2.02-164.78], respectively) 
Conclusion: The time of procedure of ESD for gastric superficial lesions is influenced by size of 
lesion (>20 mm) and location (upper third of stomach), which predict a time longer than 90 minutes. 
This can be useful for better management of workflow, operation, training of teams and anesthesic 
procedures. 
 
KEYWORDS: stomach neoplasms, gastric cancer, endoscopic gastrointestinal surgical 
procedures, length of operative time 
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INTRODUCTION 
 
Endoscopic Submucosal Dissection (ESD) is an endoscopic technique used for treatment of 
gastric superficial lesions [1]. It has been widely used in countries such as Korea and Japan, but its use 
only widespread in the Western countries in the last decade [2]. Although having successful results [3-
5], ESD requires a high level of expertise in order to reach the desired outcomes [6, 7] .  
Specifically, longer procedural times are related to a higher level of complications [8] such as 
delayed bleeding [9], perforation [10, 11], post-operative pneumonia [11-13] and other clinical 
complications related to premedication and a heavy workload for patients [7].  Moreover, previous 
retrospective studies have shown that time of procedure can be influenced by different factors such as 
existence of fibrosis [14, 15], presence of ulceration [7, 15-17], area of the resected specimen [7, 16-19], 
location on the upper portion of the stomach [7, 16-19], adhesion [19] and presence of a scar [7]. 
Therefore, it is essential to take these factors into account in the pre-operatory period, since they can 
influence the workflow for ESD such as allocation of type of rooms and anesthesic procedures, and level 
of training of teams [11]. 
The present work aims at addressing the procedure time of ESD for removal of superficial 
gastric lesions and to define which patients’ characteristics, lesions’ features and procedure variables 
may be predictive of longer procedural times. 
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MATERIALS AND METHODS 
 
A. Type of study and selection of patients 
 
Our study reports a retrospective cohort of 162 consecutively patients (with 195 gastric neoplastic 
lesions) that were referred to the Portuguese Institute of Oncology – Porto (IPO) from March 2003 to 
April 2013 for assessment and treatment of gastric superficial neoplasias. This study was conducted in 
accordance with the ethical principles of the Declaration of Helsinki, in compliance with good clinical 
practice. 
 
All patients were referred for endoscopic treatment after a multidisciplinary oncology group 
decision and full medical and anesthesiology evaluation. Both oral and written informed consent was 
given by patients. All the endoscopic procedures performed on IPO during this period were screened by 
their report on the institute database, followed by analysis of the clinical record of the patient.  
 
For the purpose of this study, only cases treated by ESD, without ulcerative findings on the lesion, 
and technically performed with IT-knife were selected. Fifty three procedures were excluded because 
they were treated by Endoscopic Mucosal Resection (EMRc). Of the ESD procedures, one was excluded 
because Flex-knife was used along with IT knife, six were excluded because Diathermic loop was used 
along with IT-knife and two were excluded because cap was used along with IT-Knife. Six procedures 
were excluded due to incomplete information regarding time of procedure. 
 
B. Description of endoscopic resection techniques 
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Two operators effectuated the endoscopic procedures (MDR and PPN). MDR received training in 
Japan and in live animal courses before introducing the technique in the Hospital. PPN had animal 
training and then gradually begun the endoscopic procedures under MDR supervision in 2010 [20, 21]. 
Lateral margins of each lesion were always determined by chromoendoscopy with indigo carmine 1% 
[22-24] or with virtual chromoendoscopy using HR-NBI (applying Pimentel-Nunes et al classification for 
delimitation of lesions [25]) and small marks were made 2-5 mm from the edges of the lesion using 
needle-knife coagulation. The technique of Endoscopic Submucosal Dissection (ESD) was initiated after 
the submucosal injection of the lesion with an epinephrine and saline solution (1:100000) and a few 
drops of methylene blue. After that to obtain access to the submucosal layer 3 to 4 small mucosal 
incisions using needle-knife were made. Then, an IT-knife (Olympus) in the Endocut mode was used to 
do the circumference of the lesion outside the coagulation markers. Complete dissection of the lesion 
was performed using Endocut mode (Olympus electrosurgical unit) with further submucosal injections 
as needed being made throughout the procedure.  
All procedures were performed under deep sedation or general anesthesia (with propofol and 
fentanyl) supervised by an anesthesiology team.  
 
C. Definitions: procedural time and potential predictive factors 
 
Procedural time was defined as the time of anesthesia, in minutes, reported in patients’ clinical files 
by the anesteshiology team. Thereafter, two groups were created according to a time shorter or longer 
than 90 minutes of procedure. 
In order to determine the influential factors on procedure time the following variables were 
analyzed: 
- Regarding the lesion: Gross cross-sectional dimension (measured endoscopically) in 
millimeters(mm), followed by sub-grouping in lesions ≤20 mm (absolute indication for 
endoscopic resection on differentiated lesions without ulcerative findings [26]) and >20 mm,  
histopathological findings at diagnostic biopsy (low-grade dysplasia, high grade dysplasia or 
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T1a), Location (upper, middle and lower third of the stomach), macroscopic type (organized by 
Paris classification [27], followed by sub-grouping in depressed and non-depressed lesions) and 
Histopathological definitive classification defined by the presence or absence of submucosal 
invasion. 
- Regarding the patient: age, gender, presence of co-morbidities, previous suspension of anti-
platelet drugs and general condition of the patient, evaluated by the American Society of 
Anaesthesiology score (ASA 1,2,3,4 or 5) [28]. 
- Regarding the procedure: existence and type of complications.  
 
D. Statistical Analysis 
Statistical Package for Social Sciences (SPSS 21.0 Package Facility, SPSS Inc, IL, USA) was used for 
data support and analysis. Analysis was performed using descriptive statistics methods, as well as 
Kruksal-Wallis test for analysis with time as a continuous variable, and Chi-Square and Fisher’s Exact test 
for analysis of dichotomic variables. Logistic regression was used to estimate OR for individual variables 
in multivariate analysis. A value of p<0.05 was considered to be statistically significant.  
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RESULTS 
 
Characteristics of lesions 
Of the 127 lesions, 55% were performed on male patients with an average age of 69 (±10.9) 
years old and a median of 71 (IQR 61-77). Eight (6%) lesions were located on the upper third, 27 (21%) 
on the middle third and 92 (72%) were located on the lower third. The median time of procedure was of 
85 minutes (IQR 55-130). The median tumor size was of 20 mm (IQR 15-30).  
 
Factors predictive of ESD procedure time 
Tumor size, location and the ASA score were significantly associated with procedure time (see 
Table 1). Specifically, a procedure for a lesion >20 mm,  located at the upper third of the stomach and in 
a patient with an ASA of 3 were associated with longer procedure time, with results significantly 
different from the other characteristics on the same group. Other patients’, lesions’ and characteristics 
of procedure are shown on Table 1. 
Procedures were furthermore analysed in two different groups - those taking less than and 
those taking more than 90 minutes. These results are consistent with the findings on the previous 
analysis, as the majority of the cases  (72%) with a lesion ≤20 mm lasted 90 minutes or less, while the 
majority of the cases with a lesion >20 mm (66%) lasted for more than 90 minutes (p<0,001). Also, 
lesions located on the upper third took more than 90 minutes (88%), compared to lesions at other 
locations (p<0.035) and gross majority of lesions in patients with ASA1 took less than 90 minutes to 
remove (74%) while lesions on patients with ASA 3 took more than 90 minutes on 60% of the cases 
(p=0,031). Moreover, this analysis also shows that  intra-procedure complications pushed the procedure 
time to more than 90 minutes as 71% of the procedures with complications took more than 90 minutes 
(p=0.018). In multivariate analysis (Table 2), those patients harbouring lesions larger than 20 mm and 
located to the upper third showed an increased risk of 4.91 times [95% CI 2.29-10.50] and 18.26 times  
[95% CI 2.02-164.78], respectively and independently. The occurrence of complications during the 
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procedure and the ASA score do not seem to be independently predicting procedural time longer than 
90 minutes. 
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DISCUSSION 
 
To our knowledge this is the first study relating ESD time of procedure with factors from the 
lesion, patient and the procedure itself in Western countries. We showed that lesions with more than 20 
mm, located on the upper third of the stomach and in patients with other co-morbidities have a time of 
procedure significantly higher than smaller lesions, on middle and lower stomach and in patients with 
less co-morbidities. Larger lesions and lesions on the upper third are independent predictors for longer 
procedure time. Our results may permit to establish these factors relevant for planning and 
management of these patients.   
 
Predictive factors of prolonged time of procedure 
Comparing the different characteristics of the lesions, a cross sectional dimension >20 mm had 
longer procedure times when compared to lesions ≤20 mm [120 (IQR 80-147.50) minutes vs 65 (IQR 45-
110) minutes, p<0.001). Moreover, when the lesion was located on the upper third the median time was 
of 145 (IQR 115-253.75) minutes, significantly different from times recorded for lesions on the lower 
third with a median time of 80 (IQR 46.25-120) minutes, p=0.022. In what relates to the general 
condition of the patient, measured by the ASA Score, ASA 3 patients had a median procedure time of 
120 (IQR 62.5-165) minutes, clearly longer than patients with ASA 1 with a median time of 65 (IQR 40-
95) minutes, p=0.011. We also showed that these same characteristics tend to be associated with a 
procedure longer than 90 minutes. In fact, the size and location were independently associated with a 
time longer than 90 minutes whereas the risk profile of patients and/or the evidence of complications 
(bleeding) during the procedures were not independent.   
The reasons why the first two factors can act as predictors for a longer time of procedure can 
be easily explained - a larger lesion will obviously require a higher area to be dissected and therefore 
more time; the location at the upper third, due to the position required for the scope and the wall 
characteristics, require more technical skills [7, 29, 30]. Nevertheless, for the other two factors we may 
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have different reasons not to observe them as independent predictive factors – bleeding is expected 
more often in lesions in the upper third [31] and ASA 3 patients prevalence is very low and they tend to 
be older [median age of 75 (IQR 69.5-80) vs 70 (IQR 59-76) on ASA 1 and 2, p=0.005] what may lead to 
larger [median dimension of 30 mm (IQR 18-30) on ASA 3 vs 20 mm (IQR 15-25) on ASA 1 and 2 , 
p=0.037] and more advanced lesions.  
 
Predictive factors compared to western series 
Moreover, the majority of our findings are in accordance with previous findings in eastern 
series, specifically in what regards to size and location of lesion [7, 15-19]. 
Goto et al. [16] have even developed a formula to predict the time of procedure based on size 
of lesion, location on the upper third and presence of ulceration. Comparing to our results, and 
considering the non-existence of ulcerated lesions on this series, for a lesion of 20 mm or more and 
located on the upper third, its predicted time of procedure is never less than 86 minutes which is in 
accordance with our findings that those two factors are associated with a procedure time longer than 90 
minutes. 
Ahn et al. [18] also presented results that are consistent with our findings as the predicted 
times of procedure for lesions on the upper third with more than 30 mm are always superior to 90 
minutes. However, it doesn’t have the same conclusion to lesions between 21 and 30 mm. 
Regarding the intra-procedure complications predicting a longer time of procedure (>90 
minutes) it is in agreement with previous findings by Yamamoto et al. [32] stating that uncontrolled 
hemorrhage makes the procedure lengthier.  
We have also linked a higher ASA score to a prolonged procedure time. However, this finding 
contradicts Kim et al. [33] if we assume that a ASA 3 is similar to their’s high risk group defined as having 
one or more co-morbidity states. However, it is not clear if this contradiction is real or if it is due to 
different classification systems and it was not confirmed as an independent factor. 
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Limitations 
One of the limitations of our study has to do with the standard used to calculate time of 
procedure, based on the time of anesthesia. This means that our times of procedure can be slightly 
superior to the ones found on other studies that, for instance, count the time only on the beginning of 
lesion’s marking. Nevertheless, the mean time of procedure on this series is similar to times reported on 
different eastern series.  However, it can have an impact on the finding of the relation with the ASA 
score, as this one could relate directly to time of anesthesia and not with time of procedure. Also, it has 
also been reported on literature that many times the ASA Score is subjective to inter-observer variations 
[34].  Therefore, this finding should be looked with special attention. 
However, future studies should focus on the analysis of time of anesthesia and time of 
procedure itself alone, evaluated at the same time, to give us a perspective on the impact of 
complications of the procedure itself or anesthesic complications on the global time. 
Another limitation has to do with the evaluation of size being done with a cut-off point in the 
20 mm, a methodological option that has to do with the size of our series not allowing comparisons in 
smaller groups. 
A different limitation has to do with the fact that we only considered IT-knife for analysis for 
the scope of this study as previous studies refer that different knives have different times of procedure 
associated [35]. However, the option here was purely methodological as we had cases on our series with 
other knives, but the choice of other knives or concomitant knives with IT-knife was based on the fact 
that lesions were identified as more complicated and lengthy, that made us to opt to focus on only one 
knife, so this bias was not present on this study. Anyway, further studies comparing times of procedure 
with different knives can be an interesting are for research. 
Finally, we do not have consistently recorded data for fibrosis and existence of scar throughout 
the observation period, bringing to the surface the limitation of this study being a retrospective study 
and subsequently the comparisons with other works. The definition of long-term prospective studies on 
this area with the focus on studying factors influencing time of procedure are the key for obtaining 
consistent and comparable data worldwide. 
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Conclusion 
In summary, we found that lesions on the upper stomach, greater than  20 mm and in patients 
with significant co-morbidities can increase the time of procedure and it is expected that it will last more 
than 90 minutes, with the first two being independent predictors. It is important to keep in mind if these 
3 factors are present on a certain lesion before the procedure, so an adequate planning of operation, 
human resources and anesthesic method can be performed, therefore allowing a increased efficacy and 
efficiency. 
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   Time     
Characteristics n median (IQR) p value < 90 min > 90 min P value 
Procedures (total) 127 85 (55-130)     
Gender   0.443    
Male 70 97.5 (50-140)  34(49%) 36(51%) 0.065 
Female 57 80 (60-120)  37(65%) 20(35%)  
Age§ 71 (61-77)  0.705    
<= 65 42 85 (43.75 -121.25)  25(60%) 17(40%) 0.564 
>65 85 90 (60-140)  46 (54%) 39(46%)  
ASA   0.011*    
ASA 1 31 65 (40-95)  23(74%) 8 (26%) 0.031* 
ASA 2 71 90 (55-130)  38(54%) 33 (46%)  
ASA 3 25 120 (62.50-165)  10(40%) 15(60%)  
Co-morbidities   0.125    
Yes 92 90 (30-112.75)  47(51%) 45(49%) 0.076 
No 35 72.5 (55-140)  24(69%) 11(31%)  
Anti-platelets   0.153    
Yes 25 105 (60-187.5)  12(48%) 13(52%) 0.374 
No 102 85 (48.75-126.25)  59(58%) 43(42%)  
Suspension of anti-platelets   0.764    
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Yes 14 117.5 (60-200)  5(36%) 9(64%) 0.416 
No 8 102.5 (52.50-201.25)  4(50%) 4(50%)  
Size of lesion   <0.001    
<= 20 mm 74 65 (45-110)  53(72%) 21(28%) <0.001 
>20  mm 53 120 (80-147.5)  18(34%) 35(66%)  
Histopathology at biopsy   0.521    
LGD 40 75 (46.25-125)  26(65%) 14(35%) 0.367 
HGD 57 90 (52.50-137.50)  29(51%) 28(49%)  
Adenocarcinoma 30 90 (60-130)  16(53%) 14(47%)  
Type of lesion   0.891    
Naive  121 85 (55-130)  68(56%) 53(44%) 0.542 
Recidive 6 95 (29.75-156)  3(50%) 3(50%)  
Location   0.022**    
Upper third 8 145 (115-253.75)  1 (12%) 7(88%) 0.035** 
Middle third 27 90 (60-180)  15(56%) 12(44%)  
Lower third 92 80 (46.25-120)  55(60%) 37(40%)  
Macroscopic features   0.833    
Depressed lesions   60 87.5 (60-130)  36(60%) 24(40%) 0.379 
Non depressed lesions 67 85 (45-140)  35(52%) 32(48%)  
Submucosal invasion   0.289    
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Yes 14 115 (72.5-135)  6(43%) 8(57%) 0.297 
No 113 85 (52.50-130)  65(58%) 48(42%)  
Complications   0.069    
Yes 17 130 (50-200)  5(29%) 12(71%) 0.018 
No 110 84 (53.75-122.75)  66(60%) 44(40%)  
* Statistically significant for comparison between ASA1 and ASA3 
** Statistically significant for comparison between Upper third and Lower third 
§ Median Age (IQR) 
IQR, interquartile range; min, minutes; LGD, Low-grade dysplasia; HGD, High-Grade dysplasia 
 
TABLE 1 – Characteristics of patients, lesions and procedure with univariate analysis for predictors of 
longer procedure time and procedure time greater than 90 minutes. 
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   OR (95%CI)  
Size <20 mm 1   
  > 20mm 4.91 (2.29-10.50) >0.001 
Location Lower third 1   
  Middle third 1.182 (0.46-3.07) 0.731 
  Upper third 18.26 (2.02-164.78) 0.01 
Complications No 1   
 Yes 2.84 (0.84-9.63) 0.093 
ASA 1-2 1   
 3 1.713 (0.63-4.65) 0.292 
OR, Odds Ratio; CI, Confidence Interval 
TABLE 2 – Multivariate analysis of predictors for longer procedure time (>90 min) 
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Electronic formats have created opportunities for adding
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extracting portions of articles in electronic versions.
Supplementary electronic-only material should be
submitted and sent for peer review simultaneously with the
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2. Reporting Guidelines
Reporting guidelines have been developed for different
study designs; examples include CONSORT for
randomized trials, STROBE for observational studies,
PRISMA for systematic reviews and meta-analyses, and
STARD for studies of diagnostic accuracy. Journals are
encouraged to ask authors to follow these guidelines
because they help authors describe the study in enough
detail for it to be evaluated by editors, reviewers, readers,
and other researchers evaluating the medical literature.
Authors of review manuscripts are encouraged to describe
the methods used for locating, select¬ing, extracting, and
synthesizing data; this is mandatory for systematic
reviews. Good sources for reporting guidelines are the
EQUATOR Network and the NLM's Research Reporting
Guidelines and Initiatives.
3. Manuscript Sections
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sections of all study designs and manuscript formats.
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number of tables and figures.
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with the Abstract, will make electronic retrieval of the
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important for randomized trials and systematic reviews and
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submission system. Electronic submission systems may
restrict the number of characters in the title.
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degrees should be listed, although some journals do not
publish these. The name of the department(s) and
institution(s) or organizations where the work should be
attributed should be specified. Most electronic submission
systems require that authors provide full contact
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the title page should list the corresponding authors'
telephone and fax numbers and e-mail address.
Disclaimers. An example of a disclaimer is an author's
statement that the views expressed in the submitted article
are his or her own and not an official position of the
institution or funder.
Source(s) of support. These include grants, equipment,
drugs, and/or other support that facilitated conduct of the
work described in the article or the writing of the article
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Word count. A word count for the paper's text, excluding
its abstract, acknowledgments, tables, figure legends, and
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the information contained in the paper warrants the paper's
length, and whether the submitted manuscript fits within
the journal's formats and word limits. A separate word
count for the Abstract is useful for the same reason.
Number of figures and tables. Some submission systems
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Conflict of Interest declaration. Conflict of interest
information for each author needs to be part of the
manuscript; each journal should develop standards with
regard to the form the information should take and where it
will be posted. The ICMJE has developed a uniform conflict
of interest disclosure form for use by ICMJE member
journals and the ICMJE encourages other journals to adopt
it. Despite availability of the form, editors may require
conflict of interest declarations on the manuscript title page
to save the work of collecting forms from each author prior
to making an editorial decision or to save reviewers and
readers the work of reading each author's form.
b. Abstract
Original research, systematic reviews, and meta-analyses
require structured abstracts. The abstract should provide
the context or background for the study and should state
the study's purpose, basic procedures (selection of study
participants, settings, measurements, analytical methods),
main findings (giving specific effect sizes and their
statistical and clinical significance, if possible), and
principal conclusions. It should emphasize new and
important aspects of the study or observations, note
important limitations, and not overinterpret findings. Clinical
trial abstracts should include items that the CONSORT
group has identified as essential. Funding sources should
be listed separately after the Abstract to facilitate proper
display and indexing for search retrieval by MEDLINE.
Because abstracts are the only substantive portion of the
article indexed in many electronic databases, and the only
portion many readers read, authors need to ensure that
they accurately reflect the content of the article.
Unfortunately, information in abstracts often differs from
that in the text. Authors and editors should work in the
process of revision and review to ensure that information is
consistent in both places. The format required for
structured abstracts differs from journal to journal, and
some journals use more than one format; authors need to
prepare their abstracts in the format specified by the
journal they have chosen.
The ICMJE recommends that journals publish the clinical
trial registration number at the end of the abstract. The
ICMJE also recommends that, when a registration number
is available, authors list that number the first time they use
a trial acronym to refer to the trial they are reporting or to
other trials that they mention in the manuscript.
c. Introduction
Provide a context or background for the study (that is, the
nature of the problem and its significance). State the
specific purpose or research objective of, or hypothesis
tested by, the study or observation. Cite only directly
pertinent references, and do not include data or
conclusions from the work being reported.
d. Methods
The guiding principle of the Methods section should be
clarity about how and why a study was done in a particular
way. The section should include only information that was
available at the time the plan or protocol for the study was
being written; all information obtained during the study
belongs in the Results section.
i. Selection and Description of Participants
Clearly describe the selection of observational or
experimental participants (healthy individuals or patients,
in¬cluding controls), including eligibility and exclusion
criteria and a description of the source population.
Because the relevance of such variables as age, sex, or
ethnicity is not always known at the time of study design,
researchers should aim for inclusion of representative
populations into all study types and at a minimum provide
descriptive data for these and other relevant demographic
variables. If the study was done involving an exclusive
population, for example in only one sex, authors should
justify why, except in obvious cases (e.g., prostate
cancer).” Authors should define how they measured race or
ethnicity and justify their relevance.
ii. Technical Inform ation
Specify the study's main and secondary objectives–usually
identified as primary and secondary outcomes. Identify
methods, equipment (give the manufacturer's name and
address in parentheses), and procedures in sufficient detail
to allow others to reproduce the results. Give references to
established methods, including statistical methods (see
below); provide references and brief descrip¬tions for
methods that have been published but are not well-known;
describe new or substantially modified methods, give the
reasons for using them, and evaluate their limitations.
Identify precisely all drugs and chemicals used, including
generic name(s), dose(s), and route(s) of administration.
Identify appropriate scientific names and gene names.
iii. Statistics
Describe statistical methods with enough detail to enable a
knowledgeable reader with access to the original data to
judge its appropriateness for the study and to verify the
reported results. When possible, quantify findings and
present them with appropriate indicators of mea¬surement
error or uncertainty (such as confidence intervals). Avoid
relying solely on statistical hypothesis testing, such as P
values, which fail to convey important information about
effect size and precision of estimates. References for the
design of the study and statistical methods should be to
standard works when possible (with pages stated). Define
statistical terms, abbreviations, and most symbols. Specify
the statistical software package(s) and versions used.
Distinguish prespecified from exploratory analyses,
including subgroup analyses.
e. Results
Present your results in logical sequence in the text, tables,
and figures, giving the main or most important findings first.
Do not repeat all the data in the tables or figures in the
text; emphasize or summarize only the most important
observations. Provide data on all primary and secondary
outcomes identified in the Methods Section. Extra or
supplementary materials and technical details can be
placed in an appendix where they will be accessible but
will not interrupt the flow of the text, or they can be
published solely in the electronic version of the journal.
Give numeric results not only as derivatives (for example,
percentages) but also as the absolute numbers from which
the derivatives were calculated, and specify the statistical
significance attached to them, if any. Restrict tables and
figures to those needed to explain the argument of the
paper and to assess supporting data. Use graphs as an
alternative to ta¬bles with many entries; do not duplicate
data in graphs and tables. Avoid nontechnical uses of
technical terms in statistics, such as “random” (which
implies a randomizing device), “normal,” “significant,”
“correlations,” and “sample.”
Separate reporting of data by demographic variables, such
as age and sex, facilitate pooling of data for subgroups
across studies and should be routine, unless there are
compelling reasons not to stratify reporting, which should
be explained.
f. Discussion
Emphasize the new and important aspects of the study
and the conclusions that follow from them in the context of
the totality of the best available evidence. Do not repeat in
detail data or other information given in other parts of the
manuscript, such as in the Introduction or the Results
section. For experimental studies, it is useful to begin the
discussion by briefly summarizing the main findings, then
explore possible mechanisms or explanations for these
findings, compare and contrast the results with other
relevant studies, state the limitations of the study, and
explore the implications of the findings for future research
and for clinical practice.
Link the conclusions with the goals of the study but avoid
unqualified statements and conclusions not adequately
supported by the data. In particular, distinguish between
clinical and statistical significance, and avoid making
statements on economic benefits and costs unless the
manuscript includes the appropriate economic data and
analyses. Avoid claiming priority or alluding to work that
has not been completed. State new hypotheses when
war¬ranted, but label them clearly.
g. References
i. General Considerations Related to References
Authors should provide direct references to original
research sources whenever possible. Although references
to review articles can be an efficient way to guide readers
to a body of literature, review articles do not always reflect
original work accurately. On the other hand, extensive lists
of references to original work on a topic can use excessive
space. Fewer references to key original papers often serve
as well as more exhaustive lists, particularly since
references can now be added to the electronic version of
published papers, and since electronic literature searching
allows readers to retrieve published literature efficiently.
Do not use conference abstracts as references: they can
be cited in the text, in parentheses, but not as page
footnotes. References to papers accepted but not yet
published should be designated as “in press” or
“forthcoming.” Information from manuscripts submitted but
not accepted should be cited in the text as “unpublished
observations” with written permission from the source.
Avoid citing a “personal communication” unless it provides
essential information not available from a public source, in
which case the name of the person and date of
communication should be cited in parentheses in the text.
For scientific articles, obtain written permission and
confirmation of accuracy from the source of a personal
communication.
Some but not all journals check the accuracy of all
reference citations; thus, citation errors sometimes appear
in the published version of articles. To minimize such
errors, references should be verified using either an
electronic bibliographic source, such as PubMed, or print
copies from original sources. Authors are responsible for
checking that none of the references cite retracted articles
except in the context of referring to the retraction. For
articles published in journals indexed in MEDLINE, the
ICMJE considers PubMed the authoritative source for
information about retractions. Authors can identify retracted
articles in MEDLINE by searching PubMed for "Retracted
pub¬lication [pt]", where the term "pt" in square brackets
stands for publication type, or by going directly to the
PubMed's list of retracted publications.
References should be numbered consecutively in the order
in which they are first mentioned in the text. Identify
references in text, tables, and legends by Arabic numerals
in parentheses.
References cited only in tables or figure legends should be
numbered in accordance with the sequence established by
the first identification in the text of the particular table or
figure. The titles of journals should be abbreviated
according to the style used for MEDLINE
(www.ncbi.nlm.nih.gov/nlmcatalog/journals). Journals vary
on whether they ask authors to cite electronic references
within parentheses in the text or in numbered references
following the text. Authors should consult with the journal
to which they plan to submit their work.
ii. Reference Style and Form at
References should follow the standards summarized in the
NLM's International Committee of Medical Journal Editors
(ICMJE) Recommendations for the Conduct, Reporting,
Editing and Publication of Scholarly Work in Medical
Journals: Sample References webpage and detailed in the
NLM's Citing Medicine, 2nd edition. These resources are
regularly updated as new media develop, and currently
include guidance for print documents; unpublished
material; audio and visual media; material on CD-ROM,
DVD, or disk; and material on the Internet.
h. Tables
Tables capture information concisely and display it
efficiently; they also provide information at any desired level
of detail and precision. Including data in tables rather than
text frequently makes it possible to reduce the length of
the text.
Prepare tables according to the specific journal's
requirements; to avoid errors it is best if tables can be
directly imported into the journal's publication software.
Number tables consecutively in the order of their first
citation in the text and supply a title for each. Titles in
tables should be short but self-explanatory, containing
information that allows readers to understand the table's
content without having to go back to the text. Be sure that
each table is cited in the text.
Give each column a short or an abbreviated heading.
Authors should place explanatory matter in footnotes, not
in the heading. Explain all nonstandard abbreviations in
footnotes, and use symbols to explain information if
needed. Symbols may vary from journal to journal (alphabet
letter or such symbols as *, †, ‡, §), so check each
journal's instructions for authors for required practice.
Identify statistical measures of variations, such as standard
deviation and standard error of the mean.
If you use data from another published or unpublished
source, obtain permission and acknowledge that source
fully.
Additional tables containing backup data too extensive to
publish in print may be appropriate for publication in the
electronic version of the journal, deposited with an archival
service, or made available to readers directly by the
authors. An appropriate statement should be added to the
text to inform readers that this additional information is
available and where it is located. Submit such tables for
consideration with the paper so that they will be available
to the peer reviewers.
i. Illustrations (Figures)
Digital images of manuscript illustrations should be
submitted in a suitable format for print publication. Most
submission systems have detailed instructions on the
quality of images and check them after manuscript upload.
For print submissions, figures should be either
professionally drawn and photographed, or submitted as
photographic-quality digital prints.
For X-ray films, scans, and other diagnostic images, as
well as pictures of pathology specimens or
photomicrographs, send high-resolution photographic
image files. Since blots are used as primary evidence in
many scientific articles, editors may require deposition of
the original photographs of blots on the journal's website.
Although some journals redraw figures, many do not.
Letters, numbers, and symbols on figures should therefore
be clear and consistent throughout, and large enough to
remain legible when the figure is reduced for publication.
Figures should be made as self-explanatory as possible,
since many will be used directly in slide presentations.
Titles and detailed explanations belong in the legends—not
on the illustrations themselves.
Photomicrographs should have internal scale markers.
Symbols, arrows, or letters used in photomicrographs
should contrast with the background. Explain the internal
scale and identify the method of staining in
photomicrographs.
Figures should be numbered consecutively according to
the order in which they have been cited in the text. If a
figure has been published previously, acknowledge the
original source and submit written permission from the
copyright holder to reproduce it. Permission is required
irrespective of authorship or publisher except for
documents in the public domain.
In the manuscript, legends for illustrations should be on a
separate page, with Arabic numerals corresponding to the
illustrations. When symbols, arrows, numbers, or letters
are used to identify parts of the illustrations, identify and
explain each one clearly in the legend.
j. Units of Measurement
Measurements of length, height, weight, and volume should
be reported in metric units (meter, kilogram, or liter) or their
decimal multiples.
Temperatures should be in degrees Celsius. Blood
pressures should be in millimeters of mercury, unless other
units are specifically required by the journal.
Journals vary in the units they use for reporting
hematologic, clinical chemistry, and other measurements.
Authors must consult the Information for Authors of the
particular journal and should report laboratory information in
both local and International System of Units (SI).
Editors may request that authors add alternative or non-SI
units, since SI units are not universally used. Drug
concentrations may be reported in either SI or mass units,
but the alternative should be provided in parentheses where
appropriate.
k. Abbreviations and Symbols
Use only standard abbreviations; use of nonstandard
abbreviations can be confusing to readers. Avoid
abbreviations in the title of the manuscript. The spelled-out
abbreviation followed by the abbreviation in parenthesis
should be used on first mention unless the abbreviation is a
standard unit of measurement.
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